Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
Vaccinex announced it will present new biomarker data from its Phase 1b/2 SIGNAL-AD trial and outline plans for an enlarged randomized Phase 2B SIGNAL-AD2 study of pepinemab for early Alzheimer's disease at the AAIC conference in London. The presentation will highlight evidence that pepinemab regulates glial biomarkers associated with synaptic loss and cognitive decline, supporting the hypothesis that blocking SEMA4D protects astrocyte function.
Key figures
- Drug Name
- Pepinemab
- Phase Of Trial
- Phase 2B
- Trial name 1
- SIGNAL-AD
- Trial name 2
- SIGNAL-AD2
- Conference date
- July 13, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.